ReviewPLoS pathogens2013
Determinants for the development of visceral leishmaniasis disease.
Review in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 199 citations in OpenAlex.
- Recombinant LPG3 Protein From Leishmania chagasi as an Antigen for the Diagnosis of Canine Visceral Leishmaniasis.Tropical medicine & international health : TM & IH · 2026Article
- Investigation of viscerotropism-associated genes inFrontiers in microbiology · 2026Article
- Direct sequencing of Leishmania donovani from patients in Garissa County, Northern Kenya, reveals a newly emerging intra-specific hybrid genotype.PLoS neglected tropical diseases · 2026Article
- Spatiotemporal regulation of neutrophil heterogeneity in health and disease.Human molecular genetics · 2025Review
- An overview of host immune responses against Leishmania spp. infections.Human molecular genetics · 2025Review
- Immune-Pathological Correlates of Disease Severity in New-World Kala-Azar: The Role of Parasite Load and Cytokine Profiles.Pathogens (Basel, Switzerland) · 2025Article
- Leishmaniasis in IBD Patients: Challenges of a Rare Opportunistic Disease.United European gastroenterology journal · 2025Article
- Transcriptional signatures in human macrophage-like cells infected by Leishmania infantum, Leishmania major and Leishmania tropica.PLoS neglected tropical diseases · 2024Article
- The intersection of hostMicrobiology and molecular biology reviews : MMBR · 2024Review
- Visceral Leishmaniasis in Immunocompetent Hosts in Brescia: A Case Series and Analysis of Cytokine Cascade.Microorganisms · 2024Article
- Refinement ofGenes · 2023Article
- Article
- Asymptomatic Leishmania donovani infection and associated factors among blood donors attending at Metema district Blood Bank, Northwest Ethiopia: a cross- sectional study.Archives of public health = Archives belges de sante publique · 2023Article
- Unusual Observations in Leishmaniasis-An Overview.Pathogens (Basel, Switzerland) · 2023Review
- Article
- Immunotherapy and immunochemotherapy in combating visceral leishmaniasis.Frontiers in medicine · 2023Review
- Validating Immunomodulatory Responses of r-Pathogens (Basel, Switzerland) · 2022Article
- Leishmania infantum infection does not affect the main composition of the intestinal microbiome of the Syrian hamster.Parasites & vectors · 2022Article
- Investigating theTropical medicine and infectious disease · 2022Article
- An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.Acta parasitologica · 2022Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Leishmaniasis is a vector-borne neglected tropical disease associated with a spectrum of clinical manifestations, ranging from self-healing cutaneous lesions to fatal visceral infections. Among the most important questions in Leishmania research is why some species like L. donovani infect visceral organs, whereas other species like L. major remain in the skin. The determinants of visceral leishmaniasis are still poorly understood, although genomic, immunologic, and animal models are beginning to provide important insight into this disease. In this review, we discuss the vector, host, and pathogen factors that mediate the development of visceral leishmaniasis. We examine the progression of the parasite from the initial site of sand fly bite to the visceral organs and its ability to survive there. The identification of visceral disease determinants is required to understand disease evolution, to understand visceral organ survival mechanisms, and potentially to develop better interventions for this largely neglected disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.